Limits...
Economic Impact of Dengue: Multicenter Study across Four Brazilian Regions.

Martelli CM, Siqueira JB, Parente MP, Zara AL, Oliveira CS, Braga C, Pimenta FG, Cortes F, Lopez JG, Bahia LR, Mendes MC, da Rosa MQ, de Siqueira Filha NT, Constenla D, de Souza WV - PLoS Negl Trop Dis (2015)

Bottom Line: Overall costs per case and cumulative costs were calculated from the public payer and societal perspectives.National cost estimations took into account cases reported in the official notification system (SINAN) with adjustment for underreporting of cases.We applied a probabilistic sensitivity analysis using Monte Carlo simulations with 90% certainty levels (CL).

View Article: PubMed Central - PubMed

Affiliation: Department of Public Health, Aggeu Magalhaes Research Centre, Oswaldo Cruz Foundation, Recife, Brazil; Department of Community Health, Institute of Tropical Pathology and Public Health, Federal University of Goias, Goiania, Brazil.

ABSTRACT

Background: Dengue is an increasing public health concern in Brazil. There is a need for an updated evaluation of the economic impact of dengue within the country. We undertook this multicenter study to evaluate the economic burden of dengue in Brazil.

Methods: We estimated the economic burden of dengue in Brazil for the years 2009 to 2013 and for the epidemic season of August 2012- September 2013. We conducted a multicenter cohort study across four endemic regions: Midwest, Goiania; Southeast, Belo Horizonte and Rio de Janeiro; Northeast: Teresina and Recife; and the North, Belem. Ambulatory or hospitalized cases with suspected or laboratory-confirmed dengue treated in both the private and public sectors were recruited. Interviews were scheduled for the convalescent period to ascertain characteristics of the dengue episode, date of first symptoms/signs and recovery, use of medical services, work/school absence, household spending (out-of-pocket expense) and income lost using a questionnaire developed for a previous cost study. We also extracted data from the patients' medical records for hospitalized cases. Overall costs per case and cumulative costs were calculated from the public payer and societal perspectives. National cost estimations took into account cases reported in the official notification system (SINAN) with adjustment for underreporting of cases. We applied a probabilistic sensitivity analysis using Monte Carlo simulations with 90% certainty levels (CL).

Results: We screened 2,223 cases, of which 2,035 (91.5%) symptomatic dengue cases were included in our study. The estimated cost for dengue for the epidemic season (2012-2013) in the societal perspective was US$ 468 million (90% CL: 349-590) or US$ 1,212 million (90% CL: 904-1,526) after adjusting for under-reporting. Considering the time series of dengue (2009-2013) the estimated cost of dengue varied from US$ 371 million (2009) to US$ 1,228 million (2013).

Conclusions: The economic burden associated with dengue in Brazil is substantial with large variations in reported cases and consequently costs reflecting the dynamic of dengue transmission.

No MeSH data available.


Related in: MedlinePlus

Cost distribution of dengue episode by type of care and health sector (2013 US$).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4581827&req=5

pntd.0004042.g003: Cost distribution of dengue episode by type of care and health sector (2013 US$).

Mentions: Fig 3 shows the highly-skewed cost data reported for the ambulatory and hospital cohorts stratified by public or private sector. The majority (approximately 80%) of the ambulatory cases treated in the public sector incurred costs of less than US$ 220 per dengue episode. Costs associated with ambulatory cases treated in the private sector were also skewed: few patients had costs higher than US$ 440. For the hospitalized cohort, more than 80% of the dengue episodes cost US$440 or less in the public sector.


Economic Impact of Dengue: Multicenter Study across Four Brazilian Regions.

Martelli CM, Siqueira JB, Parente MP, Zara AL, Oliveira CS, Braga C, Pimenta FG, Cortes F, Lopez JG, Bahia LR, Mendes MC, da Rosa MQ, de Siqueira Filha NT, Constenla D, de Souza WV - PLoS Negl Trop Dis (2015)

Cost distribution of dengue episode by type of care and health sector (2013 US$).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4581827&req=5

pntd.0004042.g003: Cost distribution of dengue episode by type of care and health sector (2013 US$).
Mentions: Fig 3 shows the highly-skewed cost data reported for the ambulatory and hospital cohorts stratified by public or private sector. The majority (approximately 80%) of the ambulatory cases treated in the public sector incurred costs of less than US$ 220 per dengue episode. Costs associated with ambulatory cases treated in the private sector were also skewed: few patients had costs higher than US$ 440. For the hospitalized cohort, more than 80% of the dengue episodes cost US$440 or less in the public sector.

Bottom Line: Overall costs per case and cumulative costs were calculated from the public payer and societal perspectives.National cost estimations took into account cases reported in the official notification system (SINAN) with adjustment for underreporting of cases.We applied a probabilistic sensitivity analysis using Monte Carlo simulations with 90% certainty levels (CL).

View Article: PubMed Central - PubMed

Affiliation: Department of Public Health, Aggeu Magalhaes Research Centre, Oswaldo Cruz Foundation, Recife, Brazil; Department of Community Health, Institute of Tropical Pathology and Public Health, Federal University of Goias, Goiania, Brazil.

ABSTRACT

Background: Dengue is an increasing public health concern in Brazil. There is a need for an updated evaluation of the economic impact of dengue within the country. We undertook this multicenter study to evaluate the economic burden of dengue in Brazil.

Methods: We estimated the economic burden of dengue in Brazil for the years 2009 to 2013 and for the epidemic season of August 2012- September 2013. We conducted a multicenter cohort study across four endemic regions: Midwest, Goiania; Southeast, Belo Horizonte and Rio de Janeiro; Northeast: Teresina and Recife; and the North, Belem. Ambulatory or hospitalized cases with suspected or laboratory-confirmed dengue treated in both the private and public sectors were recruited. Interviews were scheduled for the convalescent period to ascertain characteristics of the dengue episode, date of first symptoms/signs and recovery, use of medical services, work/school absence, household spending (out-of-pocket expense) and income lost using a questionnaire developed for a previous cost study. We also extracted data from the patients' medical records for hospitalized cases. Overall costs per case and cumulative costs were calculated from the public payer and societal perspectives. National cost estimations took into account cases reported in the official notification system (SINAN) with adjustment for underreporting of cases. We applied a probabilistic sensitivity analysis using Monte Carlo simulations with 90% certainty levels (CL).

Results: We screened 2,223 cases, of which 2,035 (91.5%) symptomatic dengue cases were included in our study. The estimated cost for dengue for the epidemic season (2012-2013) in the societal perspective was US$ 468 million (90% CL: 349-590) or US$ 1,212 million (90% CL: 904-1,526) after adjusting for under-reporting. Considering the time series of dengue (2009-2013) the estimated cost of dengue varied from US$ 371 million (2009) to US$ 1,228 million (2013).

Conclusions: The economic burden associated with dengue in Brazil is substantial with large variations in reported cases and consequently costs reflecting the dynamic of dengue transmission.

No MeSH data available.


Related in: MedlinePlus